16 Analysts Have This To Say About Elevance Health
Portfolio Pulse from Benzinga Insights
Elevance Health (NYSE:ELV) has been analyzed by 16 analysts over the past three months, showing a range of perspectives from bullish to somewhat bullish. The average 12-month price target has increased to $605.69, with a high estimate of $649.00 and a low estimate of $557.00. Recent analyst actions include several rating raises and price target adjustments, indicating a generally positive outlook.
June 24, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Elevance Health has received a generally positive outlook from 16 analysts over the past three months, with several rating raises and price target adjustments. The average 12-month price target has increased to $605.69, indicating a positive sentiment among analysts.
The majority of analysts have a positive outlook on Elevance Health, with several raising their ratings and price targets. This suggests a likely positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100